Ramipril + Amlodipine + Atorvastatin [RAA]
Benefits at a glance
- Approved in EU
- Improving Patient´s adherence
- In accordance with latest scientific studies (START, SECURE)
- Development Kick-off
- Formulation Development
- Pilot BE
- Scale Up
- Pivotal BE
- 6 M Stability
With our new fixed dose combination, we strive to treat two related cardiovascular diseases with one convenient tablet. Thereby we reduce the number of individual tablets the patient must take, while providing the required medication, leading to a long-term improvement in patient satisfaction through improved quality of life.
The treatment guidelines recommend the combination of Dyslipidemia and Hypertension medications, for the two related health conditions.
With approximately 40% of people above the age of 50 suffering from hypertension, this new fixed dose combination will be a patient friendly treatment option, that offers the possibility to unlock a large market potential.